Antibe Therapeutics Inc(Pre-Merger) ATBPF

antiviral ...

[MrMugsy]

Interesting ... here is a study that shows a toe-to-toe comparison between Indomethacin and Naproxen, alone and in combination with Ketotifin (Asthma drug).

You can see why Indomethacin was chosen by ATE.

Add H2S to reduce gut blow-outs - then - likely add a superoxide scavenger to reduce ROS concerns.  Easy to see where this might be going in the ATB-344 patent.

Love it !


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065848/

[MrMugsy]

And like I said, I'm not a science guy so take these next comments loosely ... With the latest developments and understanding in Alzheimer's - where certain viruses (VZV) potentially could trigger other latent/dormant virsuses (HSV-1) - just one of many potential pathways and ... where Alzheimer's is being investigated as an auto-immune disease,  I see this toolbox being built

[Jefnan1]

Your insights are always interesting. The problem is that when they burn the cash they received before the liver problem they are done since they won't get another penny and right now they have nothing to sell. If they did don't you think that there would be some shares traded. Not just people on these sites trying to make $500

[MrMugsy]

--------------------- Cash burn is an important concern and it must be managed well. But we are drug development and now more than ever, you want to spend to grow the funnel. Running P2 an growing the funnel - that's the purpose for the cash. Seems to be well under control. $20MM is now in short term securities so they are telling us they don't need it all right now. Don't forget the

[Jefnan1]

Any time line for acute news?

[MrMugsy]

It's hard to tell. It seems there's lots of science on-the-go right now. Don't have the details - just know they are busy. Updates are lagging and it seems for good reason - won't know until the give us information. ------------------ For Example ... Expecting the commercial study for OTENA-acute and that might be a September thing. By my calculations, I see a $7.2-$9.6 BB